IZOZF - Izotropic Unveils Izoview Branding for Breast CC Platform in Development and Files Trademark Applications
(TheNewswire)
V ancouver , BC - TheNewswire - F ebruary 9, 2021 - Izotropic Corporation (“ Izotropic ” or the “ Company ”) (C NSX : IZO. CN ) (OTC: IZOZF )(FSE: 1R3 ), a company commercializing true 3D, dedicated breast CTimaging technology for the earlier detection, diagnosis and treatmentof breast cancers, is pleased to unveil its highly anticipated breastCT platform, the izoview.
Concept rendering image. Not forsale in the United States.
TRADEMARK FILINGS
The Company is adding to its intellectual propertyportfolio by filing a number of trademark applications in Canada, theUnited States and Europe. Protection is pending for the Company’srecognizable name, platform device name and logos.
CEO Robert Thast stated “Although the izoviewplatform is not yet available for sale, we’re securing criticalfoundations around the globe that will benefit the Company andpatients for years to come. We will continue to plan for the futureand identify opportunities to support the Company’s growth plans andexpedite patient access to breast CT.”
THE IZOVIEW LOGO
The word ‘isotropic’ was coined by breast CTPrincipal Founder and company Director Dr. John M. Boone to describethe technology and has since been adopted by the breast imagingindustry. Meaning ‘uniform in all directions,’ isotropic inspiredthe name of both the Company and the platform itself as it reflectsthe device’s unique 360-degree image acquisition and viewingcapabilities.
THE IZOVIEW PLATFORM
The izoview breast imaging platform will be a whole newexperience for patients, radiologists, and providers:
The patient places their own breast in the izoviewimaging cup. Patient dignity is preserved as no degrading breasthandling, or painful breast compression is required. With acomfortable face down view, natural breast orientation is maintained,producing more suitable image outputs.
The izoview imaging hardware beneath the table thencircles around the patient’s breast, producing approximately 500high-resolution images (depending on breast length) in 10 seconds,with a radiation dose comparable to 2-view mammography. A true 3Dreconstructed image (data set) is produced within 30 seconds, which aradiologist can then view from any angle like a 3D model, or slidethrough the 500 cross-sectional images individually to betterdetermine tumor size, shape, location, and relation to internal breaststructures, which is critical for surgical planning, treatmentmonitoring, and treatment delivery. When used with contrast in ongoingclinical trials, the izoview may find lesions and tumors in the 3-5mmsize range. Compared to the average-sized tumor found on screeningmammography, the izoview may offer 1-1.5 year earlier breast cancerdetection. Every month cancer treatment is delayed increases the riskof death by 10%.
The izoview presents the opportunity for a shorter workflow forproviders. Faster imaging times create the potential for a 3-foldincrease in the number of patients imaged per day, which woulddecrease wait times for critical breast imaging appointments.
ON BEHALF OF THE BOARD
investor relations inquiries contact:
Dan Sammartino
Phone: 1-778-962-0234
Email: IR@izocorp.com
For general inquiries contact:
1-833-IZOCORP
info@izocorp.com
About Izotropic Corporation
Izotropic Corporation is commercializing dedicatedbreast CT imaging technology for the earlier detection, diagnosis andtreatment of breast cancers. Extensive preliminary studies have foundthat breast CT may be able to routinely detect small breast tumors inthe 3-5 mm size range. The median size of breast cancer found usingmammography is approximately 11 mm. Routinedetection of 3 mm lesions would result in 1.5 year earlier detectionover mammography.
The initial indication for use for breast CT as adiagnostic device has been confirmed. Forthcoming business objectivesinclude identifying additional indications for use, development ofaccessories, and additional products, all aimed at making breast CT anindispensable tool for improving the outcomes of breast cancer.
Additional infor mation aboutIzotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com
Forward Looking Statements
This document may contain statements that are“Forward-Looking Statements,” which are based upon the currentestimates, assumptions, projections and expectations of thecompany’s management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify such information and statements byusing words such as “anticipate,” “believe,” “envision,”“estimate,” “expect,” “intend,” “may,” “plan,”“predict,” “project,” “target,” “potential,”“will,” “would,” “could,” “should,” “continue,”“contemplate” and other similar expressions and derivationsthereof in connection with any discussion of future events, trends orprospects or future operating or financial performance, although notall forward-looking statements contain these identifying words. Thesestatements are not guarantees of performance and involve risks anduncertainties that are difficult to control or predict, and as suchthey may cause future results of the company’s activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the companynor its shareholders, officers and consultants, shall be liable forany action and the results of any action taken by any person based onthe information contained herein, including without limitation thepurchase or sale of company securities. Nothing in this documentshould be deemed to be medical or other advice of any kind.
Copyright (c) 2021 TheNewswire - All rights reserved.